Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg

These tablets are indicated in the treatment of kidney cancer
Read Article

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (US FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Inlyta Tablets, 1 mg and 5 mg, of PF Prism C.V.

According to IQVIATM sales data for the 12 month period ending October 2020, the Inlyta Tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $518.8 million*.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

ANDA approvalAxitinib TabletsGlenmark Pharmakidney cancer drugUS FDA
Comments (0)
Add Comment